Table 3.
Viral load, genotype and fibrosis status of HCV positive patients
| Total=131 | NEXC (n=73) | DTC (n=58) | p Value |
|---|---|---|---|
| Genotype 1 (%) | 30 (41.1) | 16 (27.5) | 0.146 |
| Genotype 2 (%) | 1 (1.4) | 1 (1.7) | NS |
| Genotype 3 (%) | 42 (57.3) | 40 (68.9) | 0.205 |
| Genotype mix 1/3 | 0 | 1 (1.7) | N/A |
| Total=138 | n=77 | n=61 | |
| HCV viral load <100 000 iu/ml (%) | 28 (36.3) | 20 (32.7) | 0.720 |
| HCV viral load 100 000–600 000 iu/ml (%) | 23 (29.8) | 18 (29.5) | NS |
| HCV >600 000 iu/ml (%) | 26 (33.7) | 23 (37.7) | 0.720 |
| Total=52 | n=23 | n=29 | |
| Fibroscan score <7 kpa (%) | 18 (78.2) | 19 (65.5) | 0.368 |
| Fibroscan score 7.1–12 kpa (%) | 4 (17.3) | 8 (27,5) | 0.513 |
| Fibroscan >12 kpa (%) | 1 (4.3) | 2 (7.7) | NS |
DTC, Drug treatment centres; HCV, Hepatitis C virus; NEXC, needle exchange centres.